Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Monitoring Glucose Regulation Parameters in Veterans Living with Schizophrenia-Related Disorders and Switched from One Second-Generation Antipsychotic to Another

Garman PM, Ried LD, Bengston MA, Hsu C. Monitoring Glucose Regulation Parameters in Veterans Living with Schizophrenia-Related Disorders and Switched from One Second-Generation Antipsychotic to Another. Poster session presented at: Academy of Managed Care Pharmacy Annual Meeting; 2007 Apr 13; San Diego, CA.




Abstract:

Background: Glucose dysregulation in schizophrenia patients is linked to second-generation antipsychotic (SGA) medications. Introduction: It is crucial that patients living with schizophrenia receive baseline glucose screening and routine monitoring. Methods: Our objectives were to 1) describe the proportion of veterans with schizophrenia-related disorders monitored and 2) examine the influences of social-demographic characteristics, hypoglycemic drug treatment, and prior monitoring on the occurrence of monitoring glucose regulation after switching SGAs. We abstracted automated medical, prescription, and administrative data from veterans (n = 1,826) who switched SGAs and were diagnosed with schizophrenia-related disorders. Outcome variables were fasting blood glucose (FBG) and glycosylated hemoglobin (HbA1c). Cumulative monitoring was calculated in 3-month increments, 180 days prior and 365 days after the index date. Predictors of glucose monitoring 1-year after switching were analyzed using multivariate logistic regression models. Results: Most veterans were male (92%) and averaged 51.6±10.6 years. The majority were White (55%), followed by Black (25%), unspecified (10%), Hispanic (9%), Asian and American Indian < 1%. Within one year after switching, 81% had a laboratory result for FBG or HbA1c. The 1-year post switch cumulative monitoring FBG and HbA1c was 80% and 31%, respectively. FBG was more likely to be monitored 1-year post SGA switch if they were monitored prior to the switch (odds ratio [OR = 3.21, p < .01), using hypoglycemic medications before the switch (OR = 1.80, p < .01), or ≥50 years (OR = 1.39, p = .01). HbA1c was more likely to be monitored if the veteran was using hypoglycemic medications before the switch (OR = 7.71, p < .01) or monitored beforehand (OR = 6.51, p < .01), ≥50 years (OR = 1.60, p < .01) or nonwhite (OR = 1.39, p = .01). Conclusions: Most veterans with schizophrenia-related disorders were monitored for glucose dysregulation within 1-year of switching SGAs. Veterans ≥50 years and receiving hypoglycemic drug treatment were most likely to be monitored after switching SGAs. Switching SGAs should trigger monitoring to allow detection of changes in glucose regulation.





Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.